Back to top
more

Ardelyx (ARDX)

(Delayed Data from NSDQ)

$6.42 USD

6.42
5,483,029

+0.11 (1.74%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $6.41 -0.01 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Ardelyx (ARDX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of -33.33% and 0.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Suncor's (SU) Q4 Earnings Preview: Key Things to Consider

by Zacks Equity Research

Suncor Energy (SU) beat the Zacks Consensus Estimate for earnings in each of the last four quarters.

Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Marathon (MRO) Q4 Earnings on Deck: Here's How It Will Fare

by Zacks Equity Research

Lower commodity price realizations and the increase in costs are likely to have impacted the fourth-quarter earnings of Marathon Oil (MRO).

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Believe Ardelyx (ARDX) Could Rally 34.84%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 34.8% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Ardelyx (ARDX) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Ardelyx (ARDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Ardelyx (ARDX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Ardelyx (ARDX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Eli Lilly (LLY) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of 0.81% and 5.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia

by Zacks Equity Research

Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.

Are Medical Stocks Lagging Arcellx (ACLX) This Year?

by Zacks Equity Research

Here is how Arcellx, Inc. (ACLX) and Ardelyx (ARDX) have performed compared to their sector so far this year.

Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 127.27% and 155.31%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia

by Zacks Equity Research

Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The stock of the company climbs 13%.

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 33.33% and 40.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of -18.18% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Ardelyx (ARDX) closed at $4.05, marking a +0.5% move from the previous day.

Ardelyx (ARDX) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 500% and 59.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Ardelyx (ARDX) closed the most recent trading day at $2.95, moving +0.34% from the previous trading session.

Are Medical Stocks Lagging Ardelyx (ARDX) This Year?

by Zacks Equity Research

Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.

Ardelyx (ARDX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Ardelyx (ARDX) closed at $3.02 in the latest trading session, marking a -1.63% move from the prior day.

Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the NDA resubmission timeline for Xphozah, tenapanor.